Scholarlink

<p>Lung cancer is the leading cause of tumor-related death in the world. Duodenal metastasis from lung adenocarcinoma is an exceptionally rare occurrence and is often asymptomatic. Currently, there are no FDA-approved, well-defined treatment guidelines for this patient subgroup, and clinical studies in this area are scarce, limited to several case reports. Further investigation is needed to identify suitable treatments for this group. Here, we present a case of lung adenocarcinoma with duodenal metastases in a patient who exhibited a notable clinical response to immunotherapy over 39 months. Due to the limited data available on duodenal metastases from lung adenocarcinoma, this case highlights the challenges faced by clinicians in managing such cases and provides new ideas for future management of the disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Durable response to immunotherapy in NSCLC with duodenal metastasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月20日

查看全文
  • Yufei Li,
  • Leichong Chen,
  • Yijin Li,
  • Qiang Luo,
  • Shuang You,
  • Yan Zong,
  • Qianwen Li,
  • Shaoxian Cheng,
  • Rui Meng

摘要

Lung cancer is the leading cause of tumor-related death in the world. Duodenal metastasis from lung adenocarcinoma is an exceptionally rare occurrence and is often asymptomatic. Currently, there are no FDA-approved, well-defined treatment guidelines for this patient subgroup, and clinical studies in this area are scarce, limited to several case reports. Further investigation is needed to identify suitable treatments for this group. Here, we present a case of lung adenocarcinoma with duodenal metastases in a patient who exhibited a notable clinical response to immunotherapy over 39 months. Due to the limited data available on duodenal metastases from lung adenocarcinoma, this case highlights the challenges faced by clinicians in managing such cases and provides new ideas for future management of the disease.